Cargando…

CREB1(K292) and HINFP(K330) as Putative Common Therapeutic Targets in Alzheimer’s and Parkinson’s Disease

[Image: see text] Integration of omics data and deciphering the mechanism of a biological regulatory network could be a promising approach to reveal the molecular mechanism involved in the progression of complex diseases, including Alzheimer’s and Parkinson’s. Despite having an overlapping mechanism...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Rohan, Kumar, Pravir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717564/
https://www.ncbi.nlm.nih.gov/pubmed/34984308
http://dx.doi.org/10.1021/acsomega.1c05827
_version_ 1784624561346576384
author Gupta, Rohan
Kumar, Pravir
author_facet Gupta, Rohan
Kumar, Pravir
author_sort Gupta, Rohan
collection PubMed
description [Image: see text] Integration of omics data and deciphering the mechanism of a biological regulatory network could be a promising approach to reveal the molecular mechanism involved in the progression of complex diseases, including Alzheimer’s and Parkinson’s. Despite having an overlapping mechanism in the etiology of Alzheimer’s disease (AD) and Parkinson’s disease (PD), the exact mechanism and signaling molecules behind them are still unknown. Further, the acetylation mechanism and histone deacetylase (HDAC) enzymes provide a positive direction toward studying the shared phenomenon between AD and PD pathogenesis. For instance, increased expression of HDACs causes a decrease in protein acetylation status, resulting in decreased cognitive and memory function. Herein, we employed an integrative approach to analyze the transcriptomics data that established a potential relationship between AD and PD. Data preprocessing and analysis of four publicly available microarray datasets revealed 10 HUB proteins, namely, CDC42, CD44, FGFR1, MYO5A, NUMA1, TUBB4B, ARHGEF9, USP5, INPP5D, and NUP93, that may be involved in the shared mechanism of AD and PD pathogenesis. Further, we identified the relationship between the HUB proteins and transcription factors that could be involved in the overlapping mechanism of AD and PD. CREB1 and HINFP were the crucial regulatory transcription factors that were involved in the AD and PD crosstalk. Further, lysine acetylation sites and HDAC enzyme prediction revealed the involvement of 15 and 27 potential lysine residues of CREB1 and HINFP, respectively. Our results highlighted the importance of HDAC1(K292) and HDAC6(K330) association with CREB1 and HINFP, respectively, in the AD and PD crosstalk. However, different datasets with a large number of samples and wet lab experimentation are required to validate and pinpoint the exact role of CREB1 and HINFP in the AD and PD crosstalk. It is also possible that the different datasets may or may not affect the results due to analysis parameters. In conclusion, our study potentially highlighted the crucial proteins, transcription factors, biological pathways, lysine residues, and HDAC enzymes shared between AD and PD at the molecular level. The findings can be used to study molecular studies to identify the possible relationship in the AD–PD crosstalk.
format Online
Article
Text
id pubmed-8717564
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-87175642022-01-03 CREB1(K292) and HINFP(K330) as Putative Common Therapeutic Targets in Alzheimer’s and Parkinson’s Disease Gupta, Rohan Kumar, Pravir ACS Omega [Image: see text] Integration of omics data and deciphering the mechanism of a biological regulatory network could be a promising approach to reveal the molecular mechanism involved in the progression of complex diseases, including Alzheimer’s and Parkinson’s. Despite having an overlapping mechanism in the etiology of Alzheimer’s disease (AD) and Parkinson’s disease (PD), the exact mechanism and signaling molecules behind them are still unknown. Further, the acetylation mechanism and histone deacetylase (HDAC) enzymes provide a positive direction toward studying the shared phenomenon between AD and PD pathogenesis. For instance, increased expression of HDACs causes a decrease in protein acetylation status, resulting in decreased cognitive and memory function. Herein, we employed an integrative approach to analyze the transcriptomics data that established a potential relationship between AD and PD. Data preprocessing and analysis of four publicly available microarray datasets revealed 10 HUB proteins, namely, CDC42, CD44, FGFR1, MYO5A, NUMA1, TUBB4B, ARHGEF9, USP5, INPP5D, and NUP93, that may be involved in the shared mechanism of AD and PD pathogenesis. Further, we identified the relationship between the HUB proteins and transcription factors that could be involved in the overlapping mechanism of AD and PD. CREB1 and HINFP were the crucial regulatory transcription factors that were involved in the AD and PD crosstalk. Further, lysine acetylation sites and HDAC enzyme prediction revealed the involvement of 15 and 27 potential lysine residues of CREB1 and HINFP, respectively. Our results highlighted the importance of HDAC1(K292) and HDAC6(K330) association with CREB1 and HINFP, respectively, in the AD and PD crosstalk. However, different datasets with a large number of samples and wet lab experimentation are required to validate and pinpoint the exact role of CREB1 and HINFP in the AD and PD crosstalk. It is also possible that the different datasets may or may not affect the results due to analysis parameters. In conclusion, our study potentially highlighted the crucial proteins, transcription factors, biological pathways, lysine residues, and HDAC enzymes shared between AD and PD at the molecular level. The findings can be used to study molecular studies to identify the possible relationship in the AD–PD crosstalk. American Chemical Society 2021-12-16 /pmc/articles/PMC8717564/ /pubmed/34984308 http://dx.doi.org/10.1021/acsomega.1c05827 Text en © 2021 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Gupta, Rohan
Kumar, Pravir
CREB1(K292) and HINFP(K330) as Putative Common Therapeutic Targets in Alzheimer’s and Parkinson’s Disease
title CREB1(K292) and HINFP(K330) as Putative Common Therapeutic Targets in Alzheimer’s and Parkinson’s Disease
title_full CREB1(K292) and HINFP(K330) as Putative Common Therapeutic Targets in Alzheimer’s and Parkinson’s Disease
title_fullStr CREB1(K292) and HINFP(K330) as Putative Common Therapeutic Targets in Alzheimer’s and Parkinson’s Disease
title_full_unstemmed CREB1(K292) and HINFP(K330) as Putative Common Therapeutic Targets in Alzheimer’s and Parkinson’s Disease
title_short CREB1(K292) and HINFP(K330) as Putative Common Therapeutic Targets in Alzheimer’s and Parkinson’s Disease
title_sort creb1(k292) and hinfp(k330) as putative common therapeutic targets in alzheimer’s and parkinson’s disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717564/
https://www.ncbi.nlm.nih.gov/pubmed/34984308
http://dx.doi.org/10.1021/acsomega.1c05827
work_keys_str_mv AT guptarohan creb1k292andhinfpk330asputativecommontherapeutictargetsinalzheimersandparkinsonsdisease
AT kumarpravir creb1k292andhinfpk330asputativecommontherapeutictargetsinalzheimersandparkinsonsdisease